FDA To Address Companion Dx Development In Separate Guidances
This article was originally published in The Gray Sheet
Executive Summary
FDA hopes to issue draft guidance on companion diagnostics this year, but the document will focus only on the process for adding a diagnostic to an already marketed drug, not simultaneous drug/diagnostic development, according to an agency official.